HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

55.300

-7.150-11.45%

Volume:5.65M

Turnover:333.63M

Market Cap:11.00B

PE:-39.44

High:62.750

Open:61.300

Low:55.300

Close:62.450

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:35.37

T/O Rate:2.85%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.402

ROE:-27.61%

ROA:-9.92%

PB:7.50

PE(LYR):-39.44

PS:53.58

Loading ...

Overview Company News Filings

Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development

THOMSON REUTERS

Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio

THOMSON REUTERS

Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing

Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%

Bulletin Express

Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing

LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares

Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC

Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme

Bulletin Express

LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan

Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme

THOMSON REUTERS

LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™

Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC

Bulletin Express

LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval

Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial

Leads Biolabs Updates Board Composition and Committee Structure

Bulletin Express

LEADS BIOLABS-B Finalises New Articles of Association: 198.89 Million Shares Authorised, Clearer Capital & Governance Framework

Bulletin Express

LEADS BIOLABS-B (09887): Dr. Wu Fenglan Appointed as Non-Executive Director

Nanjing Leads Biolabs files directors list with Hong Kong stock exchange

Nanjing Leads Biolabs appoints Wu Fenglan non-executive director

Leads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/09887/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":55.3,"timestamp":1785118149292,"preClose":62.45,"halted":0,"volume":5645600,"delay":0,"changeRate":-0.11449159327461979,"floatShares":198000000,"shares":199000000,"eps":-1.402135334572345,"marketStatus":"Trading","change":-7.15,"latestTime":"07-27 10:09:09","open":61.3,"high":62.75,"low":55.3,"amount":333629477,"amplitude":0.119295,"askPrice":55.45,"askSize":1100,"bidPrice":55.25,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-1.3638952799930995,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1785124800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":62.45,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":35.36717,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.402135,"volumeRatio":35.36717,"shares":199000000,"dividePrice":0,"high":62.75,"amplitude":0.119295,"preClose":62.45,"low":55.3,"week52Low":44.72,"pbRate":"7.50","psRate":"53.58","week52High":97.5,"institutionHeld":0,"latestPrice":55.3,"committee":-0.222222,"eps":-1.402135334572345,"divideRate":0,"volume":5645600,"delay":0,"ttmEps":-1.3638952799930995,"open":61.3,"prevYearClose":51,"prevWeekClose":62.45,"prevMonthClose":49.32,"prevQuarterClose":49.32,"fiveDayClose":64.45,"twentyDayClose":49.58,"sixtyDayClose":81.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-07-24","current":-45.803176,"percent":0.258197,"low":-76.458084,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"high":-30.202688,"avg":-41.824579,"sd":10.124459,"marketCap":12420792910},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910}],"updateTime":1785101419602},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646874382","title":"Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874382?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","HK0000500386.USD","09887","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646743858","title":"Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2646743858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646743858?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066053197.SGD","BK4599","HK0000500386.USD","LU0058720904.USD","LU0122379950.USD","BK4534","BK4568","IE00B3T34201.USD","PFE","HK0000252160.HKD","IE00BLSP4452.SGD","SG9999001176.SGD","LU0868494617.USD","IE000M9KFDE8.USD","SG9999002224.SGD","IE0002270589.USD","LU0289739699.SGD","LU0225284248.USD","SG9999013999.USD","LU0306807586.USD","IE00B19Z3581.USD","SG9999003800.SGD","BK4007","LU1023059063.AUD","LU0321505439.SGD","BK4585","LU0321505868.SGD","BK4550","HK0000252152.HKD","LU0306806265.USD","IE00B19Z3B42.SGD","LU1057294990.SGD","LU0985481810.HKD","SGXZ57979304.SGD","SG9999011175.SGD","LU0234572021.USD","LU1883839398.USD","09887","IE00BLSP4239.USD","BK1161","SG9999002232.USD","BK4533","BK4588","SG9999001176.USD","LU0456855351.SGD","BK4581","LU0170899867.USD","LU0225771236.USD","LU2596442595.SGD","LU1066051498.USD","BK4592","IE00BBT3K403.USD","LU1894683348.USD","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879406","title":"Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879406","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646879406?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:01","pubTimestamp":1782381702,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says partner Oblenio moves LBL-051 toward clinical trial start after US$62 million Series B financingNanjing Leads Biolabs’ partner Oblenio Bio closed an oversubscribed USD 62 mi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL4gVVJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113955695","title":"Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113955695","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113955695?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:04","pubTimestamp":1780661065,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced the successful completion of its H-share full circulation programme, converting 44.39 million previously unlisted domestic shares into H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117625","title":"Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641117625?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:24","pubTimestamp":1780658645,"startTime":"0","endTime":"0","summary":"Converted 44,391,598 unlisted shares into H shares; conversion completed June 4, 2026.Converted H shares began trading in Hong Kong at 9:00 a.m. on June 5, 2026.H shares rose to 197,670,289 from 153,278,691; stake increased to 99.39% from 77.07%.Unlisted shares fell to 1,221,511 from 45,613,109; stake dropped to 0.61% from 22.93%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL3LzCGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198050083","title":"LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1198050083","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198050083?lang=en_us&edition=fundamental","pubTime":"2026-06-05 08:26","pubTimestamp":1780619193,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for LEADS BIOLABS-B (09887) on June 4th. The total market value of shares deposited reached...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","161027","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651382","title":"Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651382?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:01","pubTimestamp":1779940868,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs said Phase II results for Opamtistomig  in first-line NSCLC will be presented at the 2026 WCLC on Sept. 12-15.The study tested Opamtistomig with chemotherapy, showing strong tumor responses that improved with longer follow-up across key patient subgroups.Safety remained consistent with earlier disclosures, supporting the group’s strategy to position the PD-L1/4-1BB bispecific as a broader oncology platform asset.The company cited more than 600 patients treated across programs, with escalating doses in trials without dose-limiting toxicity reported to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL104zH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158348933","title":"Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1158348933","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158348933?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:22","pubTimestamp":1779276169,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153977350","title":"LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1153977350","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153977350?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:20","pubTimestamp":1779276036,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the company has instructed the trustee to utilize plan funds, with a total maximum amount of $50 million, to acquire additional H shares through open market...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636491018","title":"Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2636491018","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636491018?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:12","pubTimestamp":1779275565,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0MR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161159700","title":"LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™","url":"https://stock-news.laohu8.com/highlight/detail?id=1161159700","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161159700?lang=en_us&edition=fundamental","pubTime":"2026-05-19 10:24","pubTimestamp":1779157465,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 4% in morning trading. As of the time of writing, the stock was up 3.21% to HK$64.35, with a turnover of HK$8.9751 million. On the news front, on May 19, LEADS...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","HK0000500386.USD","HK0000252152.HKD","BK4134","HK0000252160.HKD","III","09887","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150184251","title":"Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=1150184251","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150184251?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:22","pubTimestamp":1779146554,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. announced that China’s Center for Drug Evaluation has approved a randomized, double-blind, multi-centre Phase III study of Opamtistomig (LBL-024), a PD-L1/4-1BB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160449247","title":"LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1160449247","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160449247?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:22","pubTimestamp":1779146527,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the initiation of a confirmatory Phase 3 clinical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1223083913.SGD","CDE","LU1223082519.USD","BK4017","HK0000252152.HKD","LU1223082196.USD","09887","LU1169590202.USD","LU1169589451.USD","PD","HK0000500386.USD","BK4023","BK4134","III","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636800242","title":"Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636800242","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636800242?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:13","pubTimestamp":1779146008,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs secured clearance from China’s NMPA drug evaluator to start a confirmatory Phase III trial of Opamtistomig  with platinum chemotherapy as a first-line treatment for advanced extrapulmonary neuroendocrine carcinoma.The randomized, double-blind study follows Phase Ib/II results that the company plans to present at ESMO this year.A separate single-arm registrational study of Opamtistomig as a third-line-or-later monotherapy is slated for a BLA filing in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 18, 2026, and is solely re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2pRr1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","09887","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136090386","title":"Leads Biolabs Updates Board Composition and Committee Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=1136090386","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136090386?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:23","pubTimestamp":1778837016,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101326531","title":"LEADS BIOLABS-B Finalises New Articles of Association: 198.89 Million Shares Authorised, Clearer Capital & Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1101326531","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101326531?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:23","pubTimestamp":1778837006,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“LEADS BIOLABS-B”) published its updated Articles of Association (effective May 2026), detailing the company’s capital structure, shareholder rights and governance...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104445964","title":"LEADS BIOLABS-B (09887): Dr. Wu Fenglan Appointed as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1104445964","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104445964?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:21","pubTimestamp":1778836877,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced the appointment of Dr. Wu Fenglan as a non-executive director of the company, effective from May 15, 2026, until the conclusion of the first board term. In...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707543","title":"Nanjing Leads Biolabs files directors list with Hong Kong stock exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707543","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635707543?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:16","pubTimestamp":1778836579,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs filed updated board composition with Hong Kong Stock Exchange dated May 15, 2026.Executive directors listed as Xiaoqiang Kang, also chairman, CEO, general manager, Shoupeng Lai, Honggang Zuo.Non-executive directors listed as Yin Cheng Zhang, Renhai Chen, Fenglan Wu.Independent non-executive directors listed as Hongbing Zhang, Yilong Du, also lead independent non-executive director, Jiliu Du.Committee line-up showed Jiliu Du as audit committee chair, Hongbing Zhang as nomination committee chair, Yilong Du as remuneration committee chair.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Servic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL3R8m8W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707544","title":"Nanjing Leads Biolabs appoints Wu Fenglan non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707544","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635707544?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:16","pubTimestamp":1778836569,"startTime":"0","endTime":"0","summary":"Wu Fenglan was appointed non-executive director, effective May 15, 2026, following shareholder vote at annual general meeting.Appointment runs through expiry of first session of board, with re-election eligibility at a general meeting under company articles.Wu reported no other roles within group, no directorships at other listed companies in past three years, no share interests, no ties to directors, senior management, or major shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 15, 2026, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7pvF3v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178818679","title":"Leads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1178818679","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178818679?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:22","pubTimestamp":1778764971,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":101,"code":"91000000","status":"200"}]}}